Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT ® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news